Trial Profile
A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Etanercept (Primary) ; Hydroxychloroquine; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis; Synovitis
- Focus Therapeutic Use
- Acronyms VEDERA
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism
- 29 Jan 2020 Primary endpoint has not been met. (Clinical remission)
- 29 Jan 2020 Results published in the Annals of the Rheumatic Diseases